Skip to content
lifestyle.ideacrossing.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aligos Therapeutics
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
August 6, 2026
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
July 13, 2026
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
July 6, 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
May 27, 2026
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
May 24, 2026
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
May 24, 2026
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
May 23, 2026
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
May 21, 2026
1
2
Next Page
→